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Abstract
Background: NF1 refers to type 1 neurofibromatosis syndrome, which has been linked with
mutations of the large NF1 gene. NF1 tumor suppressor protein, neurofibromin, has been shown
to regulate ras: the NF1 protein contains a GTPase activating protein (GAP) related domain which
functions as p21rasGAP. Our studies have previously demonstrated that the NF1 protein forms a
high affinity association with cytokeratin 14 during the formation of desmosomes and
hemidesmosomes in cultured keratinocytes.
Methods: The expression of NF1 protein was studied in developing human epidermis using
western transfer analysis, indirect immunofluorescence, confocal laser scanning microscopy,
immunoelectron microscopy, and in situ hybridization.
Results: The expression of NF1 protein was noted to be highly elevated in the periderm at 8
weeks estimated gestational age (EGA) and in the basal cells at 8–14 weeks EGA. During this
period, NF1 protein was associated with cytokeratin filaments terminating to desmosomes and
hemidesmosomes. NF1 protein did not display colocalization with α -tubulin or actin of the
cytoskeleton, or with adherens junction proteins.
Conclusions: These results depict an early fetal period when the NF1 tumor suppressor is
abundantly expressed in epidermis and associated with cytokeratin filaments. This period is
characterized by the initiation of differentiation of the basal cells, maturation of the basement
membrane zone as well as accentuated formation of selected cellular junctions. NF1 tumor
suppressor may function in the regulation of epidermal histogenesis via controlling the organization
of the keratin cytoskeleton during the assembly of desmosomes and hemidesmosomes.
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Background
The epidermis is derived from the embryonic ectoderm
and is first detectable at 4 weeks estimated gestational age
(EGA). At this time, the epidermis is composed of two dis-
tinct layers of cells. The surface layer, or the periderm,
forms the outer limits of the embryo facing the amniotic
fluid. Underneath the periderm lies the basal cell layer of
the primitive epidermis. The maturation of the epidermis
includes development of the intermediate cell layers si-
multaneously with the maturation of the basement mem-
brane zone between 9 and 16 weeks EGA, shedding of the
periderm layer and final maturation into stratified squa-
mous epithelium by the beginning of the third trimester
[1–3]. The development of cellular junctions takes place
concomitantly with the morphological maturation [2,4–
6]. These events include the formation of desmosomes,
adherens junctions, tight junctions and hemidesmo-
somes. The formation of cellular junctions is important
for the proper development of epidermis, since e.g. condi-
tional ablation of α -catenin, a cytoplasmic plaque protein
of adherens junctions, in skin results in dramatic altera-
tions in the morphogenesis and differentiation of epider-
mis [7]. The formation of hemidesmosomes and
subsequent attachment of the keratinocytes to the under-
lying basement membrane is essential for the polarization
of the basal cells of epidermis. The protein plaques of con-
tact sites are connected to a specific set of cytoskeletal fil-
aments. Specifically, the junctional proteins of
desmosomes and hemidesmosomes are connected to in-
termediate filaments while adherens and tight junctions
are linked with actin microfilaments.
NF1 refers to type 1 neurofibromatosis syndrome, which
has been linked with mutations of the large NF1 gene [8–
10]. The hallmarks of NF1 include café au lait pigment
spots of the epidermis, skin freckling, cutaneous neurofi-
bromas, and Lisch nodules of the iris [9,11]. Other find-
ings often associated with NF1 include learning
disabilities, varying osseous dysplasias, optic pathway gli-
omas and predisposition to malignancies. Molecular
cloning of the entire coding sequence of the NF1 gene and
subsequent analysis of the corresponding peptide se-
quence has lead to recognition of NF1 protein (neurofi-
bromin) as a regulator of ras, or p21rasGAP [8,10,12,13].
NF1 protein regulates the levels of biologically active ras-
GTP. Ras activity is associated with the regulation of cell
growth and differentiation, including control of cytoskel-
etal organization and formation of cell-cell junctions
[7,14]. The NF1 protein has been referred to as a tumor
suppressor as cells of malignant peripheral nerve sheath
tumors of neurofibromatosis patients may display loss of
heterozygosity of the NF1 gene [15]. In addition, somatic
mutations of NF1 gene have also been found in colon ad-
enocarcinoma, myelodysplastic syndrome, and anaplastic
astrocytoma tissues of otherwise healthy persons [16,17].
Furthermore, the levels of NF1 protein and/or mRNA
have been reported to be altered in certain proliferative
diseases, such as transitional cell carcinoma, basal cell car-
cinoma, astrocytoma, pheochromocytoma, meningioma,
and psoriasis [18–22].
Several studies implicate that NF1 protein has a crucial
role during the development. Mice carrying a ho-
mozygous null mutation at the NF1 locus die in utero ap-
parently due to the severe malformations in heart [23].
Unlike in adult tissues, NF1 protein is ubiquitously ex-
pressed during the development. The expression level and
pattern of NF1 protein have been noted to change mark-
edly and rapidly during the development in mice and men
[24,25]. These rapid changes have been considered to be
related to some of the major morphological changes oc-
curring in tissues e.g. heart [26,27].
In order to reveal the functions of NF1 protein at the mo-
lecular level, interactions of the NF1 protein with cy-
toskeletal and plasma membrane components have been
studied. Recent keratinocyte culture studies have demon-
strated that the NF1 tumor suppressor factor forms a high
affinity association with cytokeratin 14 during the short
period when the formation of desmosomes and
hemidesmosomes takes place [28]. NF1 protein becomes
rapidly associated with intermediate filament cytoskele-
ton (cytokeratin 14), desmoplakin, and β 4 integrin, when
cultured human keratinocytes are induced to differentiate
and form cell-cell junctions by increasing Ca2+ concentra-
tion of the cell culture medium. On the other hand, Li et
al. [29] have demonstrated differential localization of the
NF1 gene product with the F-actin or microtubule cy-
toskeleton during the differentiation of telencephalic neu-
rons. Furthermore, Hsueh et al. [30] have demonstrated
that NF1 tumor suppressor can form a bipartite interac-
tion with transmembrane proteoglycans syndecans 1–4.
The purpose of the present study was to investigate the in-
teractions of NF1 protein with cytoskeleton during the
morphogenesis of human epidermis. Developing epider-
mis provided a unique opportunity to visualize cytoskele-
tal and junctional proteins together with NF1 protein in
vivo. The results indicated interaction of NF1 protein with
cytokeratin 14 during the polarization of basal cells and
the maturation of intercellular junctions.
Methods
Tissue samples and keratinocyte cell cultures
Skin samples from 15 normal fetuses aged 8, 10, 10, 11,
12, 12, 13, 13, 14, 14, 15, 16, 17, 18 and 21 gestational
weeks were obtained from the Department of Obstetrics
and Gynecology, University Hospital of Turku, Finland. A
sample of neonatal skin was obtained from the Depart-
ment of Pathology, University of Turku, Finland. AdultBMC Dermatology 2002, 2 http://www.biomedcentral.com/1471-5945/2/10
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skin samples were obtained from plastic surgical opera-
tions carried out for cosmetic reasons from healthy per-
sons at the University Hospital of Turku, Finland. All the
tissue samples were obtained with the appropriate ap-
proval of the Joint Ethical Committee of the University
Hospital of Turku and the University of Turku, Finland.
The tissue samples were used for the following experi-
ments. Primary cultures of normal human keratinocytes
were established from adult skin samples and cultured as
described earlier by Pummi et al. [6].
Primary antibodies
A commercial polyclonal affinity-purified rabbit antibody
NF1GRP(D) raised against synthetic peptide correspond-
ing to amino acids 2798 – 2818 of the predicted NF1 gene
product was used for Western blotting, indirect immun-
ofluorescence, immunoelectron microscopy, avidin-bi-
otin immunolabeling, and coimmunoprecipitation (sc-
67, Santa Cruz Biotechnology, Santa Cruz, CA) [8]. The
dilution used for indirect immunofluorescence varied
from 1:10 in neonatal and adult skin to 1:500 in fetal
samples. Other antibodies specific for NF1 protein were
the affinity-purified polyclonal NF1ab67 recognizing a
peptide sequence encoded by exon 23a and the polyclo-
nal antiserum NF1as159 recognizing a peptide sequence
at the carboxyterminal end of NF1 protein. These antibod-
ies have been characterized earlier by Hermonen et al. [20]
and Koivunen et al. [28]. Other primary antibodies used
in indirect immunofluorescence were mouse monoclonal
antibodies to human E-cadherin (13-1700; Zymed Labo-
ratories Inc., San Francisco, CA); actin (1378 996) and
desmoplakin I and II (881 147) both from Boehringer
Mannheim Biochemica, Mannheim, Germany; α -actinin
(A-5044), cytokeratin 14 (C-8791), and α -tubulin (T-
9026) from Sigma Chemical Company, St. Louis, MO; β 4
integrin (12088-019, Gibco BRL Life Technologies Inc.);
and syndecan-1 (CD138, MCA681H, Serotec, Kidlington,
UK).
Western transfer analysis
Cultured keratinocytes, adult epidermal and fetal skin
samples were homogenized in RIPA buffer [1% Igepal CA-
630, 0.5% sodium deoxycholate, and 0.1% sodium do-
decyl suphate (SDS) in phosphate buffered saline (PBS)]
supplemented with protease inhibitors (Complete, Mini,
EDTA-free Protease Inhibitors Cocktail Tablets, Boehring-
er Mannheim GmbH). Protein concentrations of soluble
fraction were detected with DC Protein Assay (Bio-Rad
Laboratories, Hercules, CA). 40 µg of cultured keratinoc-
yte and fetal preparations and 80 µg of adult epidermal
preparation were loaded on 6% SDS polyacrylamide gel.
After electrophoresis, proteins were transferred to Immo-
bilon-P filter (Millipore Corporation, Bedford, MA) and
immunolabeled with NF1GRP(D) antibody at the dilu-
tion of 1:1000. Peroxidase-linked donkey-anti-rabbit (NA
934) (Amersham International plc, Little Chalfont, Buck-
inghampshire, England) was used as secondary antibody
at the dilution of 1:10 000. Proteins were detected with
ECL (Amersham Life Sciences, Little Chalfont, England)
and the filter was exposed to autoradiographic film (East-
man Kodak, New York, NY).
Co-immunoprecipitation
Cultured keratinocytes were extracted with CB-buffer
(Coimmunoprecipitation buffer: 20 mM Tris, pH 7.4, 150
mM NaCl, 0.5% Igepal CA-630, and Complete, Mini,
EDTA-free Protease Inhibitors Cocktail Tablets, Boehring-
er Mannheim) and the protein concentrations of soluble
fraction were detected with DC Protein Assay (Bio-Rad
Laboratories). 650 µg of the cell lysate was used for the
coimmunoprecipitation. The lysate was first precleared
with 50 µl of G-sepharose (Boehringer Mannheim) for 3
h and centrifuged. 10 µl of antibody for syndecan-1 (0.1
mg/ml) was added to the supernatant and incubated for 1
h. 50 µl of G-sepharose was added and further incubated
for 12 h. The lysate was centrifuged and the pellet was
washed with CB-buffer for four times. Precipitated pro-
teins were separated from the sepharose by adding Lae-
mmli buffer and boiling the sample for 4 min. After
centrifugation, the supernatant was loaded on SDS poly-
acrylamide gel, electrophoresed, transferred to Immo-
bilon-P filter, immunolabeled with NF1GRP(D), and
detected with ECL as described above with Western blot-
ting.
Indirect immunofluorescence and confocal laser scanning 
microscopy
Indirect immunofluorescence labeling of frozen fetal, ne-
onatal, and adult skin sections and confocal laser scan-
ning microscopy of these labelings were performed as
described earlier by Pummi et al. [6]. Frozen sections of fe-
tal, neonatal and adult skin were cut on silanated glass
slides. Samples were fixed with 100% methyl alcohol and
preincubated in PBS supplemented with 1% bovine se-
rum albumin (BSA). The primary antibodies were diluted
in 1% BSA-PBS, and incubated on the samples at 4°C for
20 h. After several washes in PBS, the slides were incubat-
ed with secondary antibodies at 20°C for 1 h. The samples
were washed in PBS and mounted with Glycergel (Dako,
Glostrup, Denmark). The secondary antibody used for in-
direct immunofluorescence was tetramethylrhodamine
isothiocyanate (TRITC) conjugated swine anti-rabbit IgG
(R0156, Dako A/S). In double labelings, TRITC-conjugat-
ed swine anti-rabbit IgG was mixed with fluorescein iso-
thiocyanate (FITC)-conjugated F(ab')2 fragment of goat
anti-mouse immunoglobulins (F0479, Dako A/S) or Al-
exa Fluor™ 488 conjugated goat anti-mouse IgG (Molecu-
lar Probes, Eugene, OR). Alternatively, FITC-conjugated
swine anti-rabbit IgG (F0205, Dako A/S) was mixed with
TRITC-conjugated goat anti-mouse IgG (H+L) (115-025-BMC Dermatology 2002, 2 http://www.biomedcentral.com/1471-5945/2/10
Page 4 of 11
(page number not for citation purposes)
146, Jackson ImmunoResearch Laboratories Inc., West
Grove, PA). Confocal laser scanning microscopy was car-
ried out using Leica TCS SP Spectral confocal laser scan-
ning microscope equipped with an air-cooled Argon-
Krypton ion-laser system (Leica Microsystems Heidelberg
GmbH, Heidelberg, Germany) and Leica TCS NT software
(Version 1.6.551 Heidelberg, Germany).
Immunoelectron microscopy
The immunoelectron microscopy was performed using a
post-embedding method as described earlier by Pummi et
al. [6]. In short, 1 ×  1 mm pieces of fetal skin were fixed
with 4% paraformaldehyde and embedded in L.R. White
resin (London Resin Company Limited, Berkshire, Eng-
land). NF1GRP(D) (dilution 1:100) was used as primary
antibody and goat-anti-rabbit IgG coupled to 12 nm gold
particles (Jackson ImmunoResearch Laboratories Inc.)
was used as secondary antibody at the dilution of 1:30.
The sections were examined and photographed using
JEOL 1200SX electron microscope.
Avidin-Biotin immunolabeling
Formalin fixed and paraffin-embedded specimens were
immunolabeled with avidin-biotin method using Histo-
stain-Plus Kit (Zymed Laboratories Inc.) according to the
protocol supplied with the kit by the manufacturer.
NF1GRP(D) was used as the primary antibody at the dilu-
tion of 1:200. 3.3'-diaminobenzidine tetrahydrochloride
(DAB-Plus Kit, Zymed Laboratories Inc.) was used to vis-
ualize the antibody localization. Slides were counter-
stained with Mayer's haematoxylin (Oy Reagena LTD,
Kuopio, Finland).
In situ hybridization
In situ hybridization was performed as described previous-
ly in detail by Ylä-Outinen et al. [31]. In short, a 650 bp
mouse NF1 cDNA fragment corresponding to bases 230–
880 of human NF1 cDNA (acc:M89914) was used as a
template for the synthesis of digoxigenin labeled sense
and antisense cRNA probes. Paraffin-embedded fetal skin
sections were deparaffinized, pretreated with 0.2 M HCl,
washed in 2 mg/ml glysin-PBS, and acetylated in 0.1 M tri-
ethanolamine (pH 8.0) 0.25% acetic anhydride solution.
Slides were heated to 90°C for 5 min, cooled over ice, and
prehybridized in solution containing 50% formamide,
0.6 M NaCl, 2 mM Tris-HCl, pH 7.4, 1 mM EDTA, 1.0 mg/
ml BSA, 0.02% PVP, 0.02% Ficoll, 10 mM DTT, 0.2 mg/
ml ssDNA, and 10% dextran sulphate. Hybridization was
performed at 45°C overnight in a mixture containing pre-
hybridization solution and 300 ng of cRNA probe for each
sample. All samples were prepared as duplicate and hy-
bridized separately with sense and antisense probes.
After hybridization, the samples were washed in 4 ×  SSC
and unbound RNA probe was removed with RNase treat-
ment. The samples were washed to the final stringency of
0.1 ×  SSC, 1 mM EDTA, and 1 mM DTT at 45°C. DIG-la-
beled cRNA probe was detected with sheep anti-digoxi-
genin antibody (dilution 1:100) coupled to alkaline
phosphatase (Roche Diagnostics), which was used with
color forming substrate solution according to the protocol
provided by manufacturer.
Results
The expression of NF1 protein in epidermis and in cul-
tured keratinocytes was first assessed by western transfer
analysis. The results revealed two bands of 240 kDa and
250 kDa representative of NF1 protein in all samples, al-
though the band of 240 kDa was less prominent in cul-
tured keratinocytes (Fig 1, lane 1) and in adult epidermis
(Fig 1, lane 7) compared to the fetal skin samples (Fig 1,
lanes 2–6). 240 and 250 kDa bands positive for NF1 pro-
tein in western transfer analysis have earlier been de-
scribed in other tissues, also [8,27,32]. The expression
level of the NF1 protein was higher in cultured keratinoc-
ytes and fetal skin samples compared to the adult epider-
mis.
Indirect immunofluorescence labeling and confocal laser
scanning microscopy (CLSM) was effective in visualizing
NF1 protein in different layers of the epidermis, and in
demonstrating variable subcellular distribution patterns
of the protein within individual cells. At 8 weeks EGA, ep-
idermis consisted of two cell layers, the basal and the peri-
derm layers. Both cell layers were intensely labeled with
the C terminus-specific antibody NF1GRP(D) which re-
vealed a fibrillar labeling pattern (Fig 2a). The periderm
cells displayed a more intense immunosignal compared
to the basal cells at this two-layer stage of epidermal devel-
opment. A third, the intermediate, cell layer was detecta-
ble between the basal and the periderm cell layers at 11
weeks EGA (Fig 2b). All three cell layers were positive for
NF1 protein. The labeling pattern remained fibrillar in the
basal cells, while labeling of periderm cells had changed
into a diffuse distribution within the cytoplasm. Cells of
Figure 1
Western transfer analysis of fetal skin and adult epidermis
with NF1GRP(D) antibody. Lane 1: cultured human keratino-
cytes (40 µg). Lanes 2–3: 12-week-old fetal skin (40 µg).
Lanes 4–5: 13-week-old fetal skin (40 µg). Lane 6: 14-week-
old fetal skin (40 µg). Lane 7: adult epidermis (80 µg). The
analysis reveal typical 240 and 250 kDa bands representative
of NF1 protein.BMC Dermatology 2002, 2 http://www.biomedcentral.com/1471-5945/2/10
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the intermediate layer showed less intense immunoreac-
tion for NF1 protein.
At 13 weeks EGA, the basal cells retained the fibrillar labe-
ling pattern with NF1GRP(D) antibody (Fig 2c). Analyses
of the transverse sections of the basal cells were particular-
ly informative. Specifically, the results demonstrated that
NF1 antibody labeled a web of fibrils extending from a
perinuclear location towards the cell periphery and
desmosomes (Fig 2d; see also Fig 5B:c). At 13 weeks EGA,
the periderm cells revealed a faint and a more diffuse la-
beling pattern for the NF1 compared to the basal cells (Fig
2c). Samples of 14 weeks EGA were also labeled with two
other NF1 specific antibodies (NF1as159 and NF1ab67)
(Fig 2g,2h). Both antibodies labeled all three types of ep-
idermal cell layers. The NF1as159 antibody showed a fi-
brillar pattern in the basal cell cytoplasm (Fig 2g). NF1
isoform type II specific antibody ab67 labeled all cell lay-
ers in a more punctuate manner (Fig 2h). Between 13 and
15 weeks EGA, the expression of NF1 protein faded out in
periderm cells (data not shown).
Four distinct layers of epidermis, the basal, the spinous,
the granular, and the cornified cell layers were detectable
at 21 weeks EGA. The periderm cells had disappeared by
that time. By 21 weeks EGA and in the neonatal human
epidermis, the fibrillar labeling for the NF1 protein in ba-
sal cells was no longer detectable. The labeling pattern
had changed from fibrillar into more diffuse cytoplasmic
staining (Fig 2e,2f). Even the highest magnifications failed
to reveal the fibrillar labeling (not shown).
Figure 2
Indirect immunofluorescence labeling and CLSM analysis of developing human epidermis for NF1 protein. (a-f) Labeling with
NF1GRP(D) antibody (dilution of 1:500 in fetal samples and dilution of 1:10 in neonatal (NB) sample). (a) At 8 weeks EGA,
developing epidermis consists of basal and periderm cell layers. Both cell layers are intensely labeled and reveal a fibrillar labe-
ling pattern. Insert: higher magnification of cytoplasmic compartment of a periderm cell. (b) At 11 weeks EGA, an intermediate
cell layer is detectable between the basal and the periderm cell layers. The basal cells show a fibrillar labeling pattern, while
labeling of periderm cells is diffuse. The intermediate layer shows less intense immunoreaction for NF1 protein. (c) At 13
weeks EGA, the suprabasal epidermis consists of multiple cell layers. The basal cells show fibrillar labeling pattern for NF1 pro-
tein while the periderm cells are characterized with a diffuse and faint immunoreaction. (d) A transverse section of basal cells
at 13 weeks EGA. Cells have a perinuclear web of fibrils positive for NF1 protein (*). Some fibrils are directing towards desmo-
somes (arrows) (see also figure 5B, a and c). (e,f) In 21-week-old and in neonatal (NB) epidermis the basal cells show diffuse
cytoplasmic labeling for NF1 protein. (g) NF1 specific antiserum NF1as159 labels all epidermal cell layers at 14 weeks EGA. The
labeling is fibrillar in the basal cells. (h) Also NF1 specific antibody NF1ab67 labels all cell layers, but in a more punctuate man-
ner. Scale bars 10 µm in a-c, g, h; 5 µm in d; 20 µm in e, f. Insert in (a) 30 µm.BMC Dermatology 2002, 2 http://www.biomedcentral.com/1471-5945/2/10
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In order to localize NF1 protein at the ultrastructural level,
post-embedding immunoelectron microscopy of devel-
oping skin was performed using NF1GRP(D) antibody.
The results revealed that in basal keratinocytes, the NF1
protein was located on the bundles of cytokeratin fila-
ments, which formed a tight web around the nucleus (Fig
3a). Gold particles representative of NF1 protein were de-
tected also on cytokeratin filaments terminating to
desmosomes (Fig 3b) and hemidesmosomes (Fig 3c).
In further analyses, the expression of NF1 gene was stud-
ied by in situ hybridization and avidin-biotin immunola-
beling of paraffin embedded samples. Avidin-biotin
immunolabeling revealed a pattern corresponding to that
detected by indirect immunofluorescence. At 13 weeks
EGA, the basal and the periderm cell layers were intensely
labeled with the NF1GRP(D) antibody (Fig 4a). Also the
intermediate cells showed positive reaction located in the
cell periphery. At 18 weeks EGA, the basal cell layer re-
vealed the most intense labeling while the other layers
were less positive (Fig 4d). In situ hybridization revealed
NF1 mRNA in developing epidermis. At 13 weeks EGA,
NF1 mRNA was noted in the basal and intermediate cell
layers (Fig 4c). Subcellularly, NF1 mRNA was located at
the basal aspect of basal cells and at the cell periphery of
intermediate cells. At 18 weeks EGA, NF1 mRNA was de-
tectable near the cell membranes in the suprabasal cell
layers, while the basal cells expressed NF1 mRNA at a very
low level (Fig 4f).
To investigate the fibrillar labeling pattern of NF1 protein
in early developing epidermis in more detail, double im-
munolabelings with NF1 protein and cytoskeletal marker
proteins were carried out. At 13 weeks EGA, cytokeratin 14
antibody labeled cytoskeletal intermediate filaments of
the basal cells (Fig 5A:a,d). Some labeling was also noted
in the periderm. Immunosignals for the NF1 protein and
cytokeratin 14 showed marked colocalization on many
locations in basal cells (Fig 5A:a,d). Actin antibody la-
beled the peripheral cytoplasm of all epidermal and peri-
derm cells (Fig 5A:b,e). As the NF1 protein positive fibrils
were located closer to the nuclei and actin labeling was de-
tected more peripherally, these two components showed
separate labeling (Fig 5A:b,e). α -tubulin antibody labeled
also all epidermal cell layers, but did not colocalize with
NF1 protein (Fig 5A:c,f).
In order to evaluate the spatial relationship of NF1 posi-
tive cytokeratin fibrils with desmosomes and hemidesmo-
somes, double immunolabelings of NF1 protein with
desmosomal and hemidesmosomal marker proteins were
carried out. At 13 weeks EGA, desmoplakin, a desmosom-
al cytoplasmic plaque protein, was present in a typical
punctuate pattern at the cell-cell junction sites in all cell
layers (Fig 5B:a). However, the intercellular junction sites
of basal cells showed weaker labeling for desmoplakin.
Higher magnification revealed that NF1 positive cytoker-
atin fibrils terminated to dots of desmoplakin (Fig 5B:c).
Antibody for β 4 integrin, a transmembrane component of
hemidesmosomes, labeled the basal aspects of the basal
cells as distinct dots (Fig 5B:b,d). Higher magnification re-
Figure 3
Immunoelectron microscopy of the developing human epidermis with NF1GRP(D) antibody. Gold particles representative of
NF1 protein are located on the cytokeratin filaments (a) circumscribing the nucleus (n), (b) terminating to a desmosome, and
(c) to a hemidesmosome. Scale bars 100 nm.BMC Dermatology 2002, 2 http://www.biomedcentral.com/1471-5945/2/10
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vealed that NF1 positive cytokeratin fibrils were directed
towards the β 4 integrin dots (Fig 5B:d). By 16 weeks EGA,
labeling of β 4 integrin was intensified and changed into a
more linear labeling pattern (not shown).
The localization of NF1 protein and selected adherens
junction proteins were investigated using double immu-
nolabelings in developing epidermis at 13 weeks EGA. E-
cadherin antibody revealed the cell-cell junction sites of
the basal and intermediate cells (Fig 5C:a), but high mag-
nification showed that the immunosignals for E-cadherin
and NF1 protein were not colocalized (Fig 5C:d). Also, α -
actinin and NF1 protein were mutually exclusive (Fig
5C:b,e). β 1 integrin labeled the cell membranes of the ba-
sal cells, including the basal aspect of basal cells (Fig
5C:c). Higher magnification showed that NF1 protein
positive fibrils were terminating between the β 1 integrin
labeling at cell-cell junction sites (Fig 5C:f). Thus, immu-
nosignals for NF1 protein and adherens junction compo-
nents were separate.
Recent data by Hsueh et al. [30] demonstrated interaction
of NF1 protein and syndecans 1–4. To evaluate whether
these proteins were in close contact in keratinocytes, dou-
ble immunolabeling was performed. In developing epi-
dermis at 14 weeks EGA, syndecan-1 was localized to the
plasma membrane of keratinocytes in all epidermal layers
(Fig 6a). Potential colocalization or close spatial relation-
Figure 4
Avidin-biotin immunolabeling of NF1 protein and in situ hybridization of NF1 mRNA in developing human epidermis. (a) At 13
weeks EGA, the basal and the periderm cell layers are intensely labeled with the NF1GRP(D) antibody. Also intermediate cells
show positive reaction near cell membranes. (b) Hematoxylin-eosin staining of developing epidermis at 13 weeks EGA. (c) NF1
mRNA is noted in the basal and intermediate cell layers at 13 weeks EGA. Subcellularly, NF1 mRNA is located at the cell
periphery of intermediate cells (arrowhead). Note the positive NF1 mRNA signal at the basal aspect of basal cells at this stage
of development. Arrows point to the basement membrane zone. (d) At 18 weeks EGA, the basal cells display the most intense
immunoreaction with NF1GRP(D) antibody. (e) Hematoxylin-eosin staining of 18-week-old epidermis. (f) At 18 weeks EGA,
NF1 mRNA is detectable only in the suprabasal cell layer by in situ hybridization. The positive NF1 mRNA signal is located near
cell membranes (arrowhead). Arrows point to the basement membrane zone. Scale bars 20 µm.BMC Dermatology 2002, 2 http://www.biomedcentral.com/1471-5945/2/10
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Figure 5
A. Double immunolabeling and CLSM analysis of NF1 protein with NF1GRP(D) antibody and cytoskeletal marker proteins at
13 weeks EGA in developing human epidermis. (a) NF1 protein (green) and cytokeratin 14 (red) show colocalization (yellow)
on many locations of the basal cells. (d) High magnification reveals a marked degree of colocalization of NF1 protein and cytok-
eratin 14 labeling patterns. (b) NF1 protein (red) and actin (green) antibodies show separate labeling patterns. (e) Higher mag-
nification reveals that the NF1 positive fibrils (red) are located closer to the nuclei (n), while actin (green) is located more
peripherally. (c) NF1 protein (red) and α -tubulin (green) antibodies show separate labeling. (f) High magnification of labeling for
α -tubulin and NF1 protein. Scale bars 10 µm in a-c, 1 µm in d-f. B. Double immunolabeling and CLSM analysis for NF1 protein
with NF1GRP(D) antibody and desmoplakin or β 4 integrin in developing human epidermis at 13 weeks EGA. (a) Desmoplakin
(red) is present in all epidermal cell layers, although the basal cells show weaker labeling. Instead, NF1-specific antibody labels
the basal and the periderm cells. (c) Higher magnification reveals that cytokeratin fibrils associated with NF1 protein (green)
terminate to spots of desmoplakin (red) indicating the location of desmosomes. Insert in (c) show the location of a desmo-
plakin dot (red) at the end of a NF1 positive fibril (green). (b) β 4 integrin (red) label the basal aspect of the basal cells, while
NF1 protein (green) label the basal cell cytoplasm. (d) Higher magnification reveals that β 4 integrin dots (red) are located at
the end of NF1 positive fibrils (green). Scale bars 10 µm in a, b; 2 µm in c, d. C. Double immunolabeling and CLSM analysis of
NF1 protein with adherens junction proteins and α -actinin in developing human epidermis at 13 weeks EGA. (a) E-cadherin
antibody (green) labels the cell-cell junctions of the basal and intermediate cells. NF1GRP(D) antibody (red) show basal and
periderm cell cytoplasmic labeling. (d) Higher magnification reveals that immunosignals for E-cadherin (green) and NF1 protein
(red) are not colocalized. (b and e) Also α -actinin (green) and NF1 (red) are seen mutually exclusive. (c) β 1 integrin (green)
labels the cell membranes of the basal cells, while NF1 protein (red) labeling is cytoplasmic. (f) In higher magnification, NF1 pos-
itive fibrils (red; arrowheads) are terminating between the β 1 integrin labeling (green) at cell-cell junction sites. n, nucleus. Scale
bars 10 µm a-c; 1 µm in d-f.BMC Dermatology 2002, 2 http://www.biomedcentral.com/1471-5945/2/10
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ship of syndecan-1 with NF1 protein was noted on some
basal cells (Fig 6a,6c). However, in adult epidermis, im-
munosignals for the NF1 protein and syndecan-1 were en-
tirely separate (Fig 6b,6d). Immunoprecipitation of
keratinocyte culture lysates with syndecan-1 specific anti-
body and subsequent western analysis with NF1GRP(D)
antibody demonstrated that syndecan-1 was connected to
a small fraction of NF1 protein (Fig 7).
Discussion
The results of the present study demonstrate an early fetal
period when the NF1 tumor suppressor is abundantly ex-
pressed and associated with bundles of intermediate fila-
ments of the basal keratinocytes. This emphasizes that the
NF1 gene is developmentally regulated also in human
skin. These findings also strengthen the view that the large
NF1 protein exerts its functions through multiple molec-
ular interactions. Specifically, NF1 tumor suppressor fac-
tor associates and functions with proteins located with the
plasma membrane (p21ras, syndecans), or with cytoskel-
etal components associated with selected cellular junc-
tions (desmosomes, hemidesmosomes) [12,28,30]. The
action of NF1 protein may be analogous to e.g. fatty acid
synthase, which conducts its tasks using different sites of
the same molecule. It should also be noted that the activ-
ity of ras is associated with the regulation of cell growth
and differentiation, including control of cytoskeletal or-
ganization and formation of cell-cell junctions [7,14].
Western transfer analysis, immunolocalization and in situ
hybridization showed that the NF1 gene was abundantly
expressed in developing human epidermis. In contrast to
adult epidermis, fetal basal cells displayed a fibrillar labe-
ling pattern for NF1 protein between 8 and 14 weeks EGA.
Later during the development, the fibrillar labeling of ba-
sal cells changed into a more diffuse cytoplasmic pattern.
The fibrillar labeling pattern suggested that the NF1 pro-
tein was associated with cytoskeleton. Double immunola-
belings demonstrated a relatively high degree of
colocalization of NF1 protein and cytokeratin 14 at light
microscopic level, and immunoelectron microscopy lo-
cated NF1 protein on perinuclear keratin bundles. In de-
veloping human epidermis, NF1 protein did not show
detectable association with actin microfilaments or tubu-
lin, although in other studies and conditions, NF1 protein
has been shown to interact with these cytoskeletal compo-
nents [29].
Concomitantly with the association of NF1 protein to the
cytokeratin, the epidermis undergoes profound changes:
the stratification of epidermis, maturation of basement
membrane zone, and the formation of desmosomes and
hemidesmosomes is activated. At 9–16 weeks EGA, kera-
tin filaments become more prominent, and the number of
desmosomes increase [4]. First hemidesmosomes have
Figure 6
Double immunolabeling and CLSM analysis of developing and
adult epidermis for NF1 protein and syndecan-1. (a) At 14
weeks EGA, the NF1 protein (red) shows fibrillar pattern in
basal cells while syndecan-1 (green) is localized to the plasma
membrane of keratinocytes in all epidermal layers. Close spa-
tial distribution or colocalization (yellow) is detected on
some basal cells. (b) In adult epidermis the immunosignals for
the NF1 protein (red) and syndecan-1 (green) are completely
separate. Scale bars 10 µm in a,b, 2 µm in c,d.
Figure 7
Coimmunoprecipitation of syndecan-1 and NF1 protein.
Lane 1: Keratinocyte cell lysate was immunoprecipitated with
syndecan-1 antibody. Western transfer analysis was carried
out using NF1GRP(D) antibody. Lane 2: Parallel sample as in
lane 1, but without immunoprecipitation. Note typical ~250
kDa band representative of NF1 protein in both samples.BMC Dermatology 2002, 2 http://www.biomedcentral.com/1471-5945/2/10
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been noted at ~9 weeks EGA. Between 9 and 15 weeks
EGA the number of hemidesmosomes increases by about
fourfold, and the morphology of hemidesmosomes ma-
tures simultaneously with increased contact with interme-
diate keratin filaments [2]. NF1 protein was detected also
near the desmosomes and hemidesmosomes as indicated
by both immunoelectron microscopy and double immu-
nolabeling of NF1 protein with desmoplakin and β 4 in-
tegrin. These in vivo observations are in good agreement
with the earlier in vitro study by Koivunen et al. [28]. They
showed the association of NF1 protein with CK14-con-
taining keratin intermediate filaments during the forma-
tion of desmosomes in cultured human keratinocytes. The
present study demonstrates a similar association of NF1
protein and intermediate filaments during the formation
of intercellular junctions in vivo. Developing epidermis
thus provides a good model to study differentiation of ke-
ratinocytes in vivo, since the interactions of various cy-
toskeletal and junction proteins can be readily visualized.
The finding that NF1 specific antibodies raised against dif-
ferent peptide segments of the protein results in different
labeling is in agreement with earlier studies [20,21,28,33].
Specifically, NF1GRP(D) antibody labeled most intensely
the basal cells, while other antibodies used, NF1ab67 and
NF1as159, labeled all the developing cell layers indicating
that NF1 protein is present in the intermediate cell layers,
too. One plausible explanation is that NF1GRP(D) anti-
body may recognize only a specific type of NF1 protein
conformation.
Expression of NF1 mRNA was studied at 13 and 18 weeks
EGA using in situ hybridization. At 13 weeks, the localiza-
tion of NF1 mRNA corresponded with the immunosignal
for the NF1 protein. However, at 18 weeks, NF1 mRNA
and protein displayed differential spatial distribution
within the epidermis. Specifically, NF1 mRNA was detect-
ed in the suprabasal cells but not in the basal layer. Al-
though NF1 protein remained detectable in the basal cells
at 18 weeks EGA, the labeling pattern for NF1 protein in
the basal cells had changed to a more diffuse cytoplasmic
staining. It is thus possible that the more diffuse localiza-
tion of NF1 protein in the basal cells is associated with
downregulation of the NF1 mRNA level. These results are
in concordance with previous studies detecting NF1
mRNA in suprabasal cell layers in late developing rat epi-
dermis while basal cells contained no detectable NF1
mRNA at this stage of rat epidermal development [33].
NF1 mRNA was intracellularly distributed to the basal as-
pects of the basal cells and to the cell peripheries of inter-
mediate cells at 13 weeks EGA. These are the sites where
desmosome and hemidesmosome formation takes place
during this stage of development. Previously, Ylä-Outinen
et al. [31] have shown that NF1 mRNA is targeted to cell-
cell contact zone in cultured human keratinocytes when
they are induced to differentiate. This might be true also
in vivo, since NF1 mRNA was accounted at cell-cell and
cell-basement membrane contact zones.
Periderm cells showed profound changes in the expres-
sion pattern of NF1 protein. Our study revealed that, at 8
weeks EGA, when the desmosome formation is active in
the periderm, the periderm cells showed fibrillar labeling
for NF1 protein. By the 11th week of EGA, labeling for
NF1 protein revealed a more diffuse pattern in the peri-
derm cells, diminished thereafter, and disappeared by the
16th week EGA. This correlates with the cessation of peri-
derm cell proliferation at about 12 weeks EGA [3] and dis-
ruption of intermediate keratin filaments at 15–17 weeks
EGA [4]. After the periderm cells cease dividing, they syn-
thesize little if any protein and are gradually shed into the
amniotic fluid by the end of the third trimester [3]. The ex-
pression of NF1 protein in the periderm thus correlates
well with the periderm cell proliferation and cell junction
forming activity. This is also in concordance with previous
study on developing rat skin demonstrating NF1 protein
first in the basal and periderm cells, but later mostly in the
spinous cell layer [33].
Even though a bipartite interaction between transmem-
brane syndecans and NF1 protein has been characterized
in neurons by two hybrid method [30], the results of the
present study demonstrated only little of potential colo-
calization of NF1 protein and syndecan-1 in epidermal
keratinocytes during the development and in adult. Thus,
the conditions when NF1 protein and syndecans may in-
teract, and the cell biological significance of this interac-
tion remain to be elucidated.
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